GLP-1 Agonist Therapy Center

63-year-old male, moderate cognitive impairment and lives alone. Patient lost a significant amount of weight, frequent symptomatic hypoglycemia, including light-headedness and dizziness, requiring lowering and stopping some of his glucose lowering medications. GLP-1 was stopped and his glucose levels were in normal range. We were very clear that he should not resume his GLP-1 until we saw him again.

With Sanofi's LixiLan® filed for FDA approval, GLP-1 agonist/basal insulin combinations may be potential game changers.

Novo Nordisk announced positive results on its pipeline GLP-1 candidate, semaglutide, from the phase IIIa trial, SUSTAIN 4 and 5.

First a little explanation about the new unique product with its own delivery system. This is not only a medication but also a matchstick-sized osmotic mini pump that is the size of a match and is placed just beneath the skin to deliver a continuous and consistent flow of medication for a year.

Does liraglutide help in the reduction of cardiovascular diseases?

Is semaglutide a better way to manage type 2 diabetes?

This is the fourth drug to treat diabetes that also can reduce the risk of heart disease.

First-time data for the investigational oral formulation of Novo Nordisk's semaglutide were presented at the annual meeting of the Endocrine Society. Billed as one of the company’s brightest pipeline prospects, it has sailed through a phase II trial.

Liraglutide may help type 2 diabetes patients achieve tighter glycemic control with fewer side effects than exenatide.

Victoza LEADER trial of 9,000 adults with type 2 diabetes found that drug significantly reduced the risk of heart attack or stroke.